DavidLPorterMD

PubMed

• 1 citations
  Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel.
  Nausheen Ahmed, William Wesson, Forat Lutfi, David L Porter, Veronika Bachanova
  Blood Advances. 2024-10-22
• 2 citations
  Cytokine-mediated CAR T therapy resistance in AML.
  Anand S Bhagwat, Leonel Torres, Olga Shestova, Maksim Shestov, Patrick W Mellors
  Nature Medicine. 2024-09-27
• Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia.
  Matthew P Connor, Neeharika Prathapa, Noelle V Frey, Saar I Gill, Elizabeth O Hexner
  Haematologica. 2024-08-01

Journal Articles

• Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium Difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients  
  Edward A Stadtmauer, James K Mangan, Elizabeth O Hexner, David L Porter, Daria V Babushok, Jacqueline Smith, Craig W Freyer, Mindy Schuster, Noelle V Frey, Selina M Lu..., Clinical Infectious Diseases
• Disruption of TET2 Promotes the Therapeutic Efficacy of CD19-Targeted T Cells  
  Shannon A Carty, Carl H June, David L Porter, Bruce L Levine, Rahul M Kohli, Nature
• Non-Viral RNA Chimeric Antigen Receptor Modified T Cells in Patients with Hodgkin Lymphoma  
  Stephan A Grupp, Sunita Dwivedy Nasta, Susan R Rheingold, Daniel J Landsburg, Carl H June, Jakub Svoboda, Stephen J Schuster, Saar I Gill, David L Porter, Bruce L Levine, Blood

Abstracts/Posters

• Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas
  David L. Porter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors
  David L. Porter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Fried Frailty Phenotype Predicts Mortality for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
  David L. Porter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecl...
  David L. Porter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy
  David L. Porter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes in Aggressive B-Cell Non-Hodgkin Lymphomas with Anti-CD19 CAR T-Cell (CTL019) Products Not Meeting Commercial Release Specifications
  David L. Porter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Hospitalization Patterns with Commercial CAR T-Cell Therapy: A Single Institution Experience
  David L. Porter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• CD19-Directed CAR T-Cell (CTL019) Product Viability and Clinical Outcomes in Non-Hodgkin Lymphomas and B-Cell Acute Lymphoblastic Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Chronic Lymphocytic Leukemia Cells Impair Mitochondrial Fitness in CD8+ T Cells and Impede CAR T Cell Efficacy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Outcomes of Allogeneic Stem Cell Transplantation for AML and MDS Based on Pre-Transplant MRD Status By Next-Generation Sequencing 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018